Newland Laboratories Reports 47% Drop in Q2 Profit Amid Revenue Pressure
Newland Laboratories experiences a significant decline in profit and revenue for Q2 of FY 2026-27, reflecting ongoing market challenges.
Hyderabad, November 3 (Daily Kiran) : New Delhi, November 3 — Hyderabad-based pharmaceutical company Newland Laboratories Limited has reported disappointing financial results for the second quarter of the fiscal year 2026-27. The company’s net profit plummeted by approximately 47% year-on-year, falling to ₹51.6 crore compared to ₹96.9 crore during the same quarter last year.
According to a filing with the stock exchange, the company’s operational revenue also faced significant pressure. For the September quarter, revenue decreased by 12.5%, totaling ₹449.7 crore, down from ₹514.2 crore in the previous year’s corresponding period.
The operational profitability of Newland Laboratories saw a notable decline as well. Earnings before interest, taxes, depreciation, and amortization (EBITDA) dropped by 37.2% to ₹97.6 crore, compared to ₹155.5 crore a year prior.
This pressure on margins is evident in the EBITDA margin, which decreased from 30.2% in the same quarter last year to 21.7% this year. This decline indicates that cost pressures and relatively weak revenue growth have adversely affected the company’s profitability.
Established in 1984, Newland Laboratories is a globally active pharmaceutical manufacturing company with a presence in over 80 countries. The firm primarily operates in three business segments: Generic Drug Substances (GDS), Custom Manufacturing Solutions (CMS/CDMO), and Peptide APIs (Active Pharmaceutical Ingredients).
Newland provides end-to-end manufacturing and development services to pharmaceutical and biotech companies, ranging from pre-clinical and clinical development to commercial-scale production.
The company’s manufacturing facilities are located in Telangana, specifically in Bonthapally, Pashamylaram, and Gaddapotharam. Newland has received approvals from several major global regulatory bodies, including the US FDA, EDQM (Europe), PMDA (Japan), and TGA (Australia).
Leadership at Newland Laboratories includes Dr. Davuluri Ram Mohan Rao (Executive Chairman), Davuluri Suchet Rao (Executive Vice Chairman), and Saharsh Davuluri (CEO and Managing Director). The company employs over 2,000 staff members, including more than 360 scientists involved in research and development activities.
